Pulished Date October, 2018
ID: 3230
Share on
Share on

North America Bleeding Disorders Treatment Market By Drug Class (Fibrin Sealant, Desmopressin, Antibrinolytics, Recombinant Coagulation Factor Concentrates And Plasma Derived Coagulation Factor Concentrates), By Type (vWD, Hemophilia A, Hemophilia B) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 3230
Pages: 141

The North America Bleeding Disorders Treatment Market was worth USD 3.61 billion in 2018 and is estimated to be growing at a CAGR of 7.80%, to reach USD 5.26 billion by 2023. The market is showcasing evident potential in the mentioned forecasting period. A bleeding disorder is a condition which affects the clotting (coagulation) system of the body. If not taken care of this condition properly, serious damage can happen to body in case of any wound or cut due to excessive loss of blood from the body.

There are various types of Bleeding Disorders, but the most frequently seen cases are of Hemophilia A, Hemophilia B and von Willebrand Disease  (vWD). A bleeding Disorder is generally diagnosed by any of these three methods: Platelet Aggregation Test, Complete Blood Count (CBC) and bleeding time. There are various treatment methods depending on the type of bleeding disorder and its severity. Treatments include Iron Supplementation pills, Blood transfusion and other methods.

Because of careless unbalanced diet of teenagers now-a-days in this region, iron deficiency in their body can take place easily, which is the root cause for bleeding disorders. Also, the fact that most of the bleeding disorders are inherited and cannot be completely cured is also driving this market. On the other hand, factors such as, high cost of treatment including medication and lack of skilled practitioners to cure these type of disorders are challenging this market.

The North America market for Bleeding Disorders Treatment is broadly categorized by Drug Class and by Disorder Type. On the basis of Drug Class, it is further sub-categorized into Fibrin Sealant, Desmopressin, Antibrinolytics, Recombinant Coagulation Factor Concentrates and Plasma Derived Coagulation Factor Concentrates. On the basis of disorder type, it is sub-categorized into Hemophilia A, Hemophilia B ad vWD. The recombinant coagulation factor concentrates segment is expected to grow the fastest in the mentioned forecast period. This is because of the increased R&D in this market and increasing focus of pharmaceutical companies on recombinant products.

Geographically, North America market is further sub-categorized into US and Canada. North American Region has the largest bleeding disorders treatment market share among all the regions. US leads the way among these two nations in this region.

Some of the major companies dominating the market, by their products and services include CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen North America Services, LLC and Grifos SA.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Introduction           

                                5.1.2 Fibrin Sealant         

                                5.1.3 Desmopressin       

                                5.1.4 Antibrinolytics       

                                5.1.5 Recombinant Coagulation Factor Concentrates      

                                5.1.6 Plasma Derived Coagulation Factor Concentrates  

                                5.1.7  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.8  Market Attractiveness Analysis, By Drug Class        

                                5.1.9  Market Share Analysis, By Drug Class         

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 vWD           

                                5.2.3 Hemophilia A         

                                5.2.4 Hemophilia B          

                                5.2.5 Y-o-Y Growth Analysis, By Type     

                                5.2.6 Market Attractiveness Analysis, By Type   

                                5.2.7 Market Share Analysis, By Type     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Class

                                                6.1.3.3 By Type

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Class

                                                6.1.4.3 By Type

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Class

                                                6.1.5.3 By Type

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 CSL Behring                

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 Novo Nordisk                            

                8.4 Bayer AG                     

                8.5 Biogen Inc.                  

                8.6 Shire Plc.                      

                8.7 LLC                 

                8.8 Medline Plus                              

                8.9 Janssen Global Services                        

                8.10 Grifos SA                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Bleeding Disorders Treatment Market By Drug Class, From 2018-2023 ( USD Billion )
  2. North America Fibrin Sealant Market By Region, From 2018-2023 ( USD Billion )
  3. North America Desmopressin Market By Region, From 2018-2023 ( USD Billion )
  4. North America Antibrinolytics Market By Region, From 2018-2023 ( USD Billion )
  5. North America Recombinant Coagulation Factor Concentrates Market By Region, From 2018-2023 ( USD Billion )
  6. North America Plasma Derived Coagulation Factor Concentrates Market By Region, From 2018-2023 ( USD Billion )
  7. North America Bleeding Disorders Treatment Market By Type, From 2018-2023 ( USD Billion )
  8. North America vWD Market By Region, From 2018-2023 ( USD Billion )
  9. North America Hemophilia A Market By Region, From 2018-2023 ( USD Billion )
  10. North America Hemophilia B Market By Region, From 2018-2023 ( USD Billion )
  11. United States Bleeding Disorders Treatment Market By Drug Class, From 2018-2023 ( USD Billion )
  12. United States Bleeding Disorders Treatment Market By Type, From 2018-2023 ( USD Billion )
  13. Canada Bleeding Disorders Treatment Market By Drug Class, From 2018-2023 ( USD Billion )
  14. Canada Bleeding Disorders Treatment Market By Type, From 2018-2023 ( USD Billion )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Request Sample